1.12
+0.005(+0.45%)
Currency In USD
| Previous Close | 1.12 |
| Open | 1.13 |
| Day High | 1.13 |
| Day Low | 1.1 |
| 52-Week High | 21.49 |
| 52-Week Low | 0.96 |
| Volume | 185,449 |
| Average Volume | 428,009 |
| Market Cap | 5.76M |
| PE | -0.21 |
| EPS | -5.33 |
| Moving Average 50 Days | 1.12 |
| Moving Average 200 Days | 1.76 |
| Change | 0.01 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $11.05 as of October 25, 2025 at a share price of $1.12. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $538.46 as of October 25, 2025 at a share price of $1.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in
Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit
GlobeNewswire Inc.
Oct 16, 2025 1:15 PM GMT
THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will participate at
Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology
GlobeNewswire Inc.
Oct 09, 2025 12:45 PM GMT
With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opport